1 February 2013
Revolymer plc
("Revolymer" or "the Company")
Notice of patent infringement proceedings
Revolymer (AIM: REVO), the British polymer company developing patented products for a number of high value fast moving consumer goods ("FMCG") and industrial markets, announces that on 29 January 2013, the Company received notification from Fertin Pharma A/S and Gumlink A/S of the commencement of patent infringement proceedings against the Company in connection with the sale of its nicotine gum in Canada.
Following professional advice, management considers at this stage that there are strong grounds for rebutting this action. Revolymer accordingly intends to defend vigorously the Company's position.
Revolymer will issue a further announcement in the event that there are any material developments regarding this legal action.
Ends
For further information please contact:
|
Revolymer plc |
+44 (0) 1244 283 500 |
|
Roger Pettman Rob Cridland |
|
|
Panmure Gordon (UK) Limited |
+44 (0) 20 7886 2500 |
|
Callum Stewart / Adam James (Corporate Finance) Adam Pollock / Charles Leigh-Pemberton (Corporate Broking) |
|
|
Citigate Dewe Rogerson |
+44 (0)20 7638 9571 |
|
Simon Rigby / David Dible / Ginny Pulbrook |
About Revolymer
Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the coatings & adhesives, household products and personal care markets (together "Consumer Specialties") and the confectionery chewing gum and medicated chewing gum (together "Gum") markets.
This information is provided by RNS